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A B S T R A C T
Nuclear factor, erythroid 2-like 2 (Nrf2) is a transcription factor that has been gaining attention in the field of
pharmacology and especially in the chemoprevention of diseases such as cancer, metabolic and neurodegen-
erative diseases, etc. This is because natural compounds such as sulforaphane, which is found in broccoli sprout
extracts, can activate Nrf2. The repertoire of the roles of Nrf2 is ever increasing; besides its traditional anti-
oxidant and cytoprotective effects, Nrf2 can have other functions as a transcription factor. We have recently
shown that Nrf2 directly regulates the expression of thyroglobulin (Tg), which is the most abundant thyroidal
protein and the precursor of thyroid hormones. Two functional binding sites for Nrf2 (antioxidant response
elements, AREs) were identified in the regulatory region of the TG gene. Interestingly, we then observed that one
of these AREs harbors a rare single-nucleotide polymorphism (SNP). Also recently, we performed the first
genome-wide association study (GWAS) for common SNPs that impact the circulating levels of Tg. Based on
these investigations, we were triggered (i) to investigate whether common SNPs in the Nrf2 pathway correlate
with circulating Tg levels; and (ii) to examine whether the rare SNP in one of the TG regulatory AREs may affect
gene expression. To address the first question, we analyzed GWAS data from a general population and its two
subpopulations, one with thyroid disease and/or abnormal thyroid function tests and the other without, in which
circulating Tg levels had been measured. Statistically significant associations with Tg levels were observed in the
genes encoding Nrf2 and Keap1, including, notably, a known functional SNP in the promoter of the gene en-
coding Nrf2. Regarding the rare SNP (rs778940395) in the proximal ARE of the TG enhancer, luciferase reporter
gene expression studies in PCCL3 rat thyroid follicular cells showed that this SNP abrogated the basal and
sulforaphane- or TSH-induced luciferase activity, behaving as a complete loss-of-function mutation. Thus, both
rare and common genetic variation in the Keap1/Nrf2 pathway can impact TG expression and Tg circulating
levels, respectively.
1. Introduction
The transcription factor nuclear factor, erythroid 2 (NFE2)-like 2
(Nfe2l2), also known as NFE2-related factor 2 (Nrf2), lies central to the
regulation of a battery of antioxidant, cytoprotective and tissue-specific
homeostatic genes [1]. Under basal conditions, Nrf2 is mainly
sequestered in the cytoplasm by kelch-like ECH-associated protein 1
(Keap1), a protein tethered to the actin cytoskeleton that serves as an
adaptor facilitating the ubiquitination of Nrf2 by cullin 3 (Cul3); poly-
ubiquitinated Nrf2 is subsequently degraded by the proteasome [2].
Keap1 is a protein rich in cysteine residues, whose sulfhydryl groups act
as “sensors” for oxidative or electrophilic stimuli as they react with
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electrophilic or oxidative substances. These sulfhydryl groups also react
with natural or synthetic activators of the Nrf2 pathway, including the
so-called indirect antioxidants [3], leading to conformational changes
in Keap1 that render it unable to present Nrf2 molecules to Cul3. Thus,
de novo synthesized Nrf2 escapes Keap1/Cul3-mediated proteasomal
degradation, and it accumulates the nucleus where it regulates (mainly,
stimulates) the expression of its target genes by binding to antioxidant
response element (ARE; 5′-NTGAG/CNNNGC-3′) sequences in their
regulatory regions [4].
One of the many natural compounds that can activate the Keap1/
Nrf2 pathway is sulforaphane (1-Isothiocyanato-4-(methylsulfinyl)bu-
tane). This indirect antioxidant belongs to the group of isothiocyanates
and is derived mainly from cruciferous vegetables like broccoli sprouts.
These vegetables actually contain glucoraphanin, the precursor of sul-
foraphane, which is converted to active sulforaphane by the enzyme
myrosinase that is present in some plants as well as in the human in-
testinal microflora [5]. Sulforaphane has already been used in clinical
trials with promising results in a variety of clinical settings (cancer,
diabetes, skin disorders, heart disease, respiratory diseases, psychiatric
diseases) [6]. It is believed that the beneficial effect of Nrf2 pathway
activation by sulforaphane is not mediated only by the induction of an
antioxidant/cytoprotective response but also through other pathways
that Nrf2 can regulate in its capacity of transcription factor. For in-
stance, in the case of diabetes, induction of Nrf2 pathway by sulfor-
aphane can repress gluconeogenesis [7]. Hence, in view of the growing
interest in antioxidants as Nrf2 pathway activators, research is also
warranted not only to evaluate their effectiveness but also to identify
the proper dosing regimens, and ideally also to predict and prevent
adverse effects based on the known effects of Nrf2 on tissue-specific
homeostasis [8]. In this context, we recently investigated the role of
Nrf2 in thyroid homeostasis in mice and showed that genetic or phar-
macological activation of Nrf2, besides regulating an antioxidant pro-
gram in thyroid, can also directly activate the transcription of thyr-
oglobulin (Tg), the precursor protein of thyroid hormones, by binding
to two functional ARE sequences that are conserved between rodents
and human and reside in the distal enhancer region of the TG gene [9].
Next, to address the issue of potential thyroidal toxicity of cruciferous
vegetables preparations [10], we analyzed the serum of healthy vo-
lunteers who had ingested daily for 12 weeks a sulforaphane-rich
broccoli sprout extract as part of a previous study [11]; we observed no
adverse effect on thyroidal function, as assessed by thyroid function
tests and thyroid autoantibody levels [12].
Based on these studies, we wondered whether genetic variation in
the Nrf2 pathway among humans, in the form of either common single-
nucleotide polymorphisms (SNPs) or rare mutations, could impact the
expression of Tg and/or its circulating levels in the serum. Regarding
common SNPs, we took advantage of the first genome-wide association
study (GWAS) for Tg serum levels, which was performed in a Croatian
population and was recently published [13]. Specifically, we examined
whether SNPs in the KEAP1, NFE2L2 and CUL3 genes that had been
previously shown to be associated with other phenotypes or diseases
also had an impact on Tg levels. Regarding rare mutations, we focused
on a very rare SNP (rs778940395) in the proximal functional ARE of the
TG enhancer. The results identify common SNPs in the Nrf2 pathway
that are associated with the circulating levels of Tg; they also demon-
strate that the rare mutation in the TG completely inactivates its tran-
scriptional activity.
2. Materials and methods
2.1. Study population and SNPs
The list of SNPs investigated in this study comprised all SNPs in the
KEAP1, NFE2L2 and CUL3 genes that had been previously shown to be
associated with other phenotypes or diseases. This list was compiled
from a literature review, including both review papers of this topic
[14,15], as well as original publications. These are cited in Tables 1 and
2; the references in these Tables are not exhaustive in terms of the as-
sociated diseases and phenotypes, because the criterion for inclusion of
a SNP was the presence of at least one disease or phenotype. The dbSNP
and ClinVar databases were also searched. Only germline SNPs asso-
ciated with a disease or phenotype were included; somatic mutations
were excluded.
The population that was checked for SNPs in the Nrf2 pathway
comes from two Croatian cohorts as previously described [13] within
the 10,001 Dalmatians project [16]. Analyses of the GWAS data were
performed in three groups: (i) a population without thyroid disease and
with normal thyroid function tests, comprising 1094 subjects; this is the
population that has been previously published [13]; (ii) a population
with thyroid disease and/or abnormal thyroid function tests, com-
prising 815 subjects; and (iii) the above two groups combined, com-
prising 1909 subjects and considered as a general population. The
analyses of the GWAS data for the healthy subpopulation have been
previously described [13]; for the present work, the data from the
general population and thyroid population were also analyzed, in the
same manner as previously reported [13]. Thyroid disease and/or
Table 1
SNPs in NFE2L2, KEAP1 and CUL3 associated with various human diseases or phenotypes and with Tg levels.
Gene SNP p-value Tg* Location Functionality Disease/Phenotype**
NFE2L2 rs6706649 G: 0.0197
H: 0.086
D: 0.131
↓, allele T NC_000002.11:g.178130071C > T 2 kb upstream
variant
High cholesterol [31], ulcerative colitis [32] ,
maternal acetaminophen and asthma [33], PD [34],
ALS [35]
KEAP1 rs11668429 G: 0.086
H: 0.016
D: 0.737
↑, allele G NC_000019.9:g.10616303 T > G promoter Childhood asthma [36]
KEAP1 rs9676881 G: 0.173
H: 0.027
D: 0.864
↑, allele A NC_000019.9:g.10596780G > A 0.5 kb downstream
variant
COPD [37], diabetes [38]
KEAP1 rs1048290 G: 0.197
H: 0.03
D: 0.92
↑, allele C NC_000019.9:g.10600442G > C;
NM_012289.3:c.1413C > G (p.Leu471= )
exon 4
synonymous
variant
Renal protection against cisplatin [39], temporal
lobe epilepsy and drug-resistant epilepsy [40],
diabetes [38], cognitive impairment [41], breast
cancer [24]
For the SNPs that are within transcripts, both the mRNA (NM) and genomic (NC) references are given. Note that the minor allele always refers to the genomic
reference (NC). G: general population; H: healthy subpopulation (without any history, sign, or laboratory indication of thyroid disease); D: subpopulation with a
history, sign, or laboratory abnormality indicative of thyroid disease” (i.e., thyroid medication, thyroidectomy, thyroid autoimmunity, or levels of TSH, free T4, free
T3 and/or Tg outside the respective reference range). ALS: amyotrophic lateral sclerosis; COPD: chronic obstructive pulmonary disease; PD: Parkinson’s disease. *
Effect of the indicated minor allele on Tg levels. ↑: increase; ↓: decrease. ** Known disease/phenotype associations of the respective SNP. All SNPs with at least one
reported association are listed, but not all references are necessarily cited for each SNPs).
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abnormal thyroid function tests were defined as: thyroid medication
use, history of thyroid surgery, history of thyroid disorders, or thyroid
function tests levels out of the reference range (the parameters assessed
were TSH, free T4, free T3, Tg, Tg autoantibodies and thyroid perox-
idase autoantibodies). The study was approved by the Research Ethics
Committees in Croatia and Scotland, and all subjects gave written in-
formed consent. The analyses of the GWAS data for general population
and the healthy subpopulation have been previously described; for the
present work, the data from the thyroid population were also analyzed,
in the same manner as previously reported [13].
2.2. Blood chemistries
Concentrations of thyroid hormones, Tg and autoantibodies were
measured by immunoassay methods with the Liaison XL Biomedica
Chemiluminescence Analyzer (DiaSorin, Saluggia, Italy) as previously
described [13]. Measurements were performed in the Biochemistry
Laboratory in the Department of Nuclear Medicine at the University
Hospital of Split.
2.3. Plasmids construction
An already available luciferase reporter vector, hTGenh/prm-Luc
[17], containing the human TG upstream enhancer [18] and proximal
promoter [19] cloned upstream of the luciferase reporter gene of the
PGL3 vector (hereafter, pTg) was used to study the effect of the
rs778940395 rare polymorphism. The pTg vector was used as a tem-
plate to create a reporter bearing the rs778940395 using the Quik-
Change II Site-Directed Mutagenesis Kit (Stratagene, San Diego, CA)
according to the manufacturer’s protocol. The following primers were
used for the in vitro mutagenesis: pTG-rs_F: 5′-CCTGTGTGCTGAATCT
TTCTTGCTGGCCTGG-3′; pTG-rs_R: 5′-CCAGGCCAGCAAGAAAGATTC
AGCACACAGG-3′. A previously created pTg enhancer/promoter con-
struct bearing a mutant proximal ARE sequence (MUT) [9] was used as
a positive control. All promoters constructs were verified by Sanger
sequencing. In order to exclude any artifact arising from plasmid iso-
lation of the WT and MUT constructs, two independent plasmid pre-
parations (clones) were used in the experiments.
2.4. Cell culture
PCCL3 cells, a clonal rat thyroid follicular cell line [20], were cul-
tured in Coon’s modified Ham’s F-12 under conditions described pre-
viously [9]. Culture media, supplements, sulforaphane and bovine TSH
were all from Sigma-Aldrich (St. Louis, MO). Generation of a Nrf2
knockout PCCL3 cell line using CRISPR/Cas9 technology has been
previously described [9]. PCCL3 cells were transiently transfected with
the different pTg reporter constructs in 96-well plates in complete
medium using a 1:2 ratio of DNA and jetPRIME transfection reagent
(Polyplus-transfection, Illkirch, France) respectively. The pEGFP-N1
plasmid (Clontech, Mountain View, CA) was included in all transfection
experiments to monitor transfection efficiency and to normalize luci-
ferase activities [21]. Treatment with sulforaphane (5 µM) or vehicle
(DMSO) was performed 24 h after transfection. For TSH treatment, as
soon as 24 h had passed after transfection, cells were starved for 48 h
and then were treated with 0.5mIU/mL of TSH for 24 h. The starvation
medium (4H medium) contained 0.2% FBS and four of the six hormones
from the 6H medium [9] (TSH and insulin were excluded). Passive Lysis
Buffer (Promega, Madison, WI) was used to lyse the cells 48 h after
transfection and GFP fluorescence was measured using a NOVOstar
multi–mode reader (BMG Labtech, Ortenberg, Germany) with excita-
tion and emission wavelengths of 480 and 520 nm, respectively. The
GFP fluorescence background of non-transfected cells was used to blank
the fluorescence measurements. Then, luciferase activities were mea-
sured in the same plate using the Luciferase Assay System (Promega)
according to the manufacturer's protocol. Luciferase activities were
normalized to GFP fluorescence and relative luciferase activities were
expressed as fold change over control.
2.5. Statistics
Analyses of the GWAS data were performed as previously described
in detail [13]. Briefly, Tg levels were adjusted for age and sex using
linear regression analysis and then derived residuals were inverse
normal-transformed and included in the linear mixed model, which
accounts for population structure and relatedness. “SNPTEST” and R
software were used to identify independently associated SNPs. Even
through the data examined were derived from a GWAS, the present
study took a hypothesis-based approach, wherein only a small set of
SNPs was investigated; the statistical threshold applied was thus a p-
value< 0.05.
In the cell-based studies, the normalized luciferase ratios were
analyzed using the BootstRatio application (http://rht.iconcologia.net/
stats/br/index.html). This software tool is based on bootstrapping and
resampling methods, without any assumption on the underlying prob-
ability distribution for the data analyzed [22]. The graphs were pre-
pared using GraphPad Prism v7 (GraphPad Software, Inc., La Jolla, CA).
3. Results
3.1. SNPs in KEAP1 and NFE2L2 genes are associated with circulating Tg
levels
Several SNPs in NFE2L2 have been previously associated with var-
ious human diseases and/or phenotypes (Tables 1 and 2). Among them
are especially three functional SNPs in the promoter of NFE2L2 itself
(rs35652124, rs6706649 and rs6721961), which have been shown to
regulate its transcriptional activity with the minor alleles leading to
reduced transcription [23]. Table 1 lists the SNPs with statistically
significant p-values in the GWAS data in at least one population (gen-
eral population, health subpopulation or thyroid disease subpopula-
tion).
For NFE2L2, only rs6706649 was significantly associated with Tg
levels, and only in the general population (p=0.0197). The minor
allele was associated with lower Tg levels. This is consistent with the
fact that rs6706649 is one of the three functional SNPs in the NFE2L2
promoter [23], and our previous finding that Nrf2 has a positive impact
on the transcription of the gene encoding Tg and the thyroidal levels of
Tg protein [9].
For KEAP1, three SNPs were significantly associated with Tg levels,
all of them in the healthy population only (rs11668429, p=0.016;
rs9676881, p= 0.027; rs1048290, p=0.03). For all three, the minor
alleles were associated with higher Tg levels. Since it is not known
whether each of these three specific SNPs affects KEAP1 expression, it is
not possible to comment whether the observed directional effect (minor
alleles associated with higher Tg levels) is compatible with the afore-
mentioned positive effect of Nrf2 signaling on Tg [9]. Nevertheless, the
fact all three minor alleles significantly affect Tg levels in the same
direction (increase) is consistent with the fact that these three SNPs are
in tight linkage disequilibrium with each other, as shown by the present
data and previous work [24].
Only one SNP in the CUL3 gene has been previously reported to be
associated with a human disease or phenotype (rs2396092, associated
with esophageal squamous cell carcinoma [25]. This SNP was not as-
sociated with Tg levels in the present study (Table 2).
3.2. One of the functional Nrf2 binding sites (ARE) on TG regulating region
harbors a very rare sequence variant.
The two binding sequences through which Nrf2 upregulates TG gene
transcription, ARE1 and ARE2, are located 2.8 kb and 3.2 kb, respec-
tively, upstream of the transcription initiation site [9]. According to the
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information currently available in the Database of Single Nucleotide
Polymorphisms (dbSNP build 152), ARE1 harbors a very rare sequence
variant, rs778940395 (NC_000008.11:g.132864133 T > A; frequency:
1/30958 in GnomAD; 1/3854 in ALSPAC; 0/3708 in TWINSUK)
(Fig. 1A). As there are no published studies on this variant, we in-
vestigated its functionality in cell-based reporter gene after introducing
it in the pTg promoter/enhancer luciferase reporter construct using in
vitro mutagenesis as described above (Fig. 1B) [9].
3.3. The rs778940395 variant in the TG distal enhancer is a completely
loss-of-function in terms of transcription activity
PCCL3 rat thyroid follicular cells were transfected with different
plasmids: two clones that carry the wild-type ARE1 sequence (WT1 and
WT2, positive controls); two clones that carry the rs778940395 variant
(rs1 and rs2); or a previously generated mutant ARE1 version that we
have shown to be completely inactivating (MUT, positive control) [9]
(Fig. 1B). Both rs1 and r2 showed significantly reduced ARE-driven
luciferase activity at baseline as compared to WT1 (which was itself not
different from WT2); their activity levels were in fact not different from
those of the MUT clone (Fig. 2A). These results indicate that the
rs778940395 variant abolishes the basal transcriptional activity of
ARE1. Treatment with sulforaphane significantly induced ARE-driven
luciferase activity of the TG enhancer in the WT1 and WT2 clones, but
this induction was blunted in the rs1 and rs2 clones, again to a similar
extent as in the MUT clone (Fig. 2A). These results indicate that the
rs778940395 variant also abolishes the sulforaphane-inducible tran-
scriptional activity of ARE1. The same experiment was repeated in Nrf2
knockout PCCL3 cells engineered by CRISPR/Cas9 technology. In the
absence of Nrf2, no differences were observed either under basal con-
ditions or in response to sulforaphane treatment in any of the clones
(Fig. 2B). These data indicate that all the observed differences in
Fig. 2A are Nrf2-dependent; thus, the rs778940395 variant abolishes
the Nrf2-dependent transcriptional activity of ARE1, both the basal one
and the sulforaphane-inducible one.
We have shown previously that Nrf2 mediates the induction of the
TG promoter not only by sulforaphane but also by TSH [9]. We there-
fore repeated the experiment in PCCL3 WT cells and treated them with
TSH, as described in the Methods. As expected, TSH induced ~2.5-fold
the ARE-driven luciferase activity in WT1 and WT2 (Fig. 2C). The rs1
Fig. 1. The distal enhancer of TG harbors a
rare SNP in one of its functional Nrf2
binding sites (AREs). A. rs778940395,
T > A is located in the core sequence of one
of the two AREs in the TG enhancer. The
core ARE sequence is indicated in grey. The
nucleotide base that changes is indicated in
red. B. Plasmid constructs that express luci-
ferase under the control of the TG promoter/
enhancer used in the present study. The first
construct carries the wild-type (WT) core
proximal ARE sequence (ARE1). In the
second construct, SNP rs778940395 was
introduced in ARE1 by in vitro mutagenesis.
The third construct (MUT) carries an ARE1
modified by in vitro mutagenesis that has been previously shown to be completely inactive. Binding sites for thyroid transcription factor 1 (TTF1) and a cAMP
response element (CRE)-like potential binding site are also indicated.
Fig. 2. The rare variant rs778940395 in the proximal ARE of the TG distal enhancer leads to complete loss of basal and inducible transcriptional activity. A.
Introduction of rs778940395 abrogates the basal and sulforaphane-induced ARE1-driven TG promoter/enhancer luciferase activity. PCCL3 wild-type (WT) cells were
cultured in complete medium in 96-well plates and were transfected with different TG promoter/enhancer luciferase reporter constructs. Specifically, two clones with
wild-type (WT1 and WT2) proximal AREs, two clones carrying rs778940395 in ARE1 (rs1, rs2) and a previously validated mutant ARE1 clone were used (MUT). After
24 h, cells were treated with 5 µM sulforaphane (_SLF) or vehicle (< 0.1% dimethyl sulfoxide) as control (_C); 24 h later, cells were lysed and luciferase activity was
measured. Each column represents the mean ± SD of 7 independent experiments. *p < 0.05 vs. WT1_C; $p < 0.05 vs. WT1_SLF; #p < 0.05 vs. MUT_C; ‡p < 0.05
vs. MUT_SLF. B. Deletion of Nrf2 abrogates all changes in the ARE-driven TG promoter/enhancer luciferase activity induced by ARE1 mutation or sulforaphane
treatment. The same experiment illustrated in A was performed in Nrf2 knockout (Nrf2KO) PCCL3 cells developed by Crispr/CAS9 technology. In the absence of Nrf2,
the activity of the TG promoter/enhancer is unaffected by the presence or absence of rs77894039 as well as by treatment with sulforaphane. Each column represents
the mean ± SD of 7 independent experiments. C. Introduction of rs778940395 to the TG promoter/enhancer blunts its TSH-induced activity, behaving like the
complete loss-of-function mutant ARE version. 24 h after transfection, WT PCCL3 cells were starved in 4H medium (medium without TSH and insulin) supplemented
with 0.2% FBS for 48 h, and then they were treated or not with TSH (0.5 mU/ml) for 24 h. Each column represents the mean ± SD of 7 independent experiments.
*p < 0.05 vs. WT1_C; $p < 0.05 vs. WT1_TSH, #p < 0.05 vs. MUT_C, ‡p < 0.05 vs. MUT_TSH.
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and rs2 clones showed significantly lower inducibility (~1.5-fold),
which was again not different from that of the MUT clone (Fig. 2C).
These results indicate that the rs778940395 variant also abolishes the
TSH-inducible transcriptional activity of ARE1.
4. Discussion
Nrf2 is a proven druggable target for chemoprevention by natural
antioxidants, and compounds like sulforaphane have been used in
clinical trials in a variety of disease settings [26,27]. The emerging links
between Nrf2 and the thyroid gland suggest that further research is
warranted to better understand, and potentially also predict, whether
pharmacological manipulation of Nrf2 can impact thyroid physiology
or pathophysiology in a beneficial or detrimental manner, whether it is
neutral, or whether genetic factors can act as determinants of this re-
lationship. Indeed, human genetic studies indicate that potent activa-
tion of Nrf2 signaling throughout life can be detrimental for the thyroid;
this conclusion is drawn from the fact that two published case reports
on unrelated families from Japan have associated two different germ-
line loss-of-functions mutations in KEAP1 with familial multinodular
goiter inherited in an autosomal dominant manner [28,29]. However,
these are very rare mutations, which can be actually considered “pri-
vate”, since each of them has been documented only in a single family;
thus, the relevance for the general population remains unknown.
To the best of our knowledge, the present study is the first one to
explore the impact on the thyroid of inherited genetic variation in the
Keap1/Nrf2 pathway by focusing on variants that are likely to lead to
much more mild alterations of the pathway’s activity. The SNPs in-
cluded in the GWAS analyses are classified as common variants, which,
when associated with diseases or phenotypes, usually have small effect
sizes. The results indicate that common genetic variation in NFE2L2 or
KEAP1 is indeed associated with circulating Tg levels in the general
population or in the healthy subpopulation, respectively. Regarding the
molecular mechanism by which the SNPs affect Tg levels, because
rs6706649 is known to be associated with lower NFE2L2 expression in
in vitro studies [23], we postulate that this leads to lower basal levels
and lower activity of Nrf2, thereby causing decreased ARE-driven TG
gene transcription and ultimately decreased Tg circulating levels. We
acknowledge that this is a hypothesis, as we do not have direct mea-
sures of NFE2L2 expression or Nrf2 activity in the thyroid gland of these
subjects (this is a general limitation of association studies of the NFE2L2
functional SNPs). For the KEAP1 SNPs rs11668429, rs9676881 and
rs1048290, we postulate that the observed effects on Tg levels are also
likely mediated by altered Nrf2 activity; however, as noted in the Re-
sults, there are no published data on whether these three specific SNPs
affect KEAP1 expression. No associations were found in the sub-
population with documented or suspected thyroid disease. One likely
explanation is that thyroid disease per se or the existence of anti-Tg
antibodies can induce substantial changes in the serum Tg levels or its
measurement results, respectively, that obscure any mild impact of
genetic variations in the Nrf2 pathway. Another explanation, not mu-
tually exclusive with the aforementioned one, may be that mild impact
of the common SNPs on Tg levels is not sufficient to cause thyroid
disease. This is consistent with our recent clinical study that found no
negative impact on thyroid hormonal or autoimmune status of a sul-
foraphane-containing beverage ingested over 12 weeks [12]. Taken
together, these findings support the notion that, in contrast to potent
and continuous activation of Nrf2 by loss-of-function mutations in
KEAP1, mild or time-restricted alteration of Nrf2 pathway activity is
more likely to be well tolerated by the thyroid.
Unlike the common SNPs interrogated in the GWAS, rs778940395 is
very rare. Nevertheless, similar to the common SNPs, it can also be
reasonably expected to have an overall mild effect at the molecular
level. This is because, due to its rarity, it is highly unlikely to be en-
countered in the homozygous state. We hypothesize that rs778940395
abolishes the DNA binding of Nrf2, which we have previously shown to
bind directly to the wild-type ARE1 [9]. Even though the mutant ARE1
has no transcriptional activity, a subject heterozygous for rs778940395
would still normally possess three functional AREs in his/her distal Tg
enhancer, i.e., the ARE1 on the wild-type allele plus the two wild-type
ARE2s. Hence, it can be estimated that rs778940395 would lower Tg
mRNA levels by 25%. Even though ARE2 also regulates positively the
basal and inducible activity of the TG enhancer [9], it does not harbor
any SNPs, and thus the present analyses focused on the polymorphic
ARE1.
One limitation of the present study is that, due to the rarity of
rs778940395, we were not able to have access to carriers of this SNPs in
order to document whether they have a thyroidal phenotype or not.
Therefore, we believe that it is important to make these functional data
publicly available, in order to motivate the identification and thyroidal
phenotyping of carriers of this rare variant, possibly in the context of
high-scale genotyping efforts like the 100′000 genomes project [30]. In
the same spirit, we acknowledge that the “non-healthy” subpopulation
analyzed in the present study was not homogeneous in terms of the
underlying thyroid disease or thyroid function test abnormality. We
therefore suggest that studies are thus warranted to examine the genetic
association of SNPs in the Nrf2 pathway with specific thyroid diseases.
In conclusion, the present study demonstrates that both rare and
common genetic variation in the Keap1/Nrf2 pathway can impact TG
expression and Tg circulating levels, respectively, and it sets the stage
for follow-up studies that will characterize associations of genetic var-
iants in the pathway with specific thyroid diseases. Such studies are
useful to predict the impact of pharmacological manipulation of Nrf2
on the thyroid and the underlying mechanisms, and they are com-
plementary to clinical pharmacological studies with compounds that
activate or inhibit Nrf2, of which the natural antioxidant sulforaphane
serves as a prototype.
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